News
3h
Zacks Investment Research on MSNLilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...
Eli Lilly (LLY 1.15%) and Novo Nordisk (NVO 0.14%) are two phenomenal growth stocks that investors probably can't go wrong ...
Eli Lilly has outpaced Ozempic-maker Novo Nordisk in the race to develop new incretin drugs.The company is set to capture 50% ...
Deep-pocketed investors have adopted a bullish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...
Indianapolis: Eli Lilly and Company has received approval from the U.S. Food and Drug Administration (FDA) for a label update ...
Shares of Eli Lilly & Co. LLY rose 1.19% to $786.92 Wednesday, on what proved to be an all-around great trading session for ...
While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...
Eli Lilly and Company (NYSE:LLY) is one of the 10 Best Non-Tech Stocks to Buy and Hold For 3 Years. On June 22, Eli Lilly and ...
The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...
The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...
See the latest Eli Lilly and Co stock price (LLY:XNYS), related news, valuation, dividends and more to help you make your investing decisions.
The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results